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Abstract
Background and purpose
Polymorphisms in coagulation genes have been associated with early-onset ischemic
stroke. Here we pursue an a priori hypothesis that genetic variation in the endothelial-based
receptors of the thrombomodulin−protein C system (THBD and PROCR) may similarly be
associated with early-onset ischemic stroke. We explored this hypothesis utilizing a multi-
stage design of discovery and replication.
Methods
Discovery was performed in the Genetics-of-Early-Onset Stroke (GEOS) Study, a biracial
population-based case-control study of ischemic stroke among men and women aged 15–
49 including 829 cases of first ischemic stroke (42.2% African-American) and 850 age-com-
parable stroke-free controls (38.1% African-American). Twenty-four single-nucleotide-poly-
morphisms (SNPs) in THBD and 22 SNPs in PROCR were evaluated. Following LD pruning
(r2�0.8), we advanced uncorrelated SNPs forward for association analyses. Associated
SNPs were evaluated for replication in an early-onset ischemic stroke population (onset-
age<60 years) consisting of 3676 cases and 21118 non-stroke controls from 6 case–control
studies. Lastly, we determined if the replicated SNPs also associated with older-onset ische-
mic stroke in the METASTROKE data-base.
Results
Among GEOS Caucasians, PROCR rs9574, which was in strong LD with 8 other SNPs, and
one additional independent SNP rs2069951, were significantly associated with ischemic
stroke (rs9574, OR = 1.33, p = 0.003; rs2069951, OR = 1.80, p = 0.006) using an additive-
model adjusting for age, gender and population-structure. Adjusting for risk factors did not
change the associations; however, associations were strengthened among those without
risk factors. PROCR rs9574 also associated with early-onset ischemic stroke in the replica-
tion sample (OR = 1.08, p = 0.015), but not older-onset stroke. There were no PROCR asso-
ciations in African-Americans, nor were there any THBD associations in either ethnicity.
Conclusion
PROCR polymorphisms are associated with early-onset ischemic stroke in Caucasians.
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Introduction
Hemostasis is a dynamic balance between factors that promote clot formation and factors that
promote antithrombotic activity and/or fibrinolysis. Central to this balance is the thrombomo-
dulin-protein C antithrombotic system that is located on the endothelial surface, which plays a
key role in regulating both coagulation and inflammation. Thrombomodulin forms a 1:1 com-
plex with thrombin on the vascular endothelium, thereby inhibiting the procoagulant actions
of thrombin and converting protein C to activated protein C [1]. Activated protein C promotes
fibrinolysis, inhibits thrombosis by inactivating coagulation factors Va and VIIIa, and reduces
inflammation by decreasing white blood cell and nuclear factor kappa-B activation [2–5]. The
activation of protein C by the thrombin-thrombomodulin complex is enhanced when the sub-
strate protein C is presented by the endothelial cell protein C receptor. These relationships are
demonstrated in Fig 1. Given the central role that the thrombomodulin-protein C pathway
plays in thrombosis and inflammation, the genes encoding these receptor proteins are promis-
ing stroke susceptibility candidate genes. Prior genetic studies across the cardiovascular disease
(CVD) spectrum have demonstrated increased risk in younger (vs. older) patients [6], includ-
ing thrombosis [7]. Variants in other prothrombotic genes have also previously been associ-
ated with ischemic stroke, again, more consistently with early-onset versus later-onset disease
[8,9,10]. As such, an a priori hypothesis to evaluate these 2 genes in the setting of ischemic
stroke was developed and successfully funded. To this end we tested the hypothesis that THBD
(OMIM 188040) and PROCR (OMIM 600646) variants are associated with early-onset ische-
mic stroke using a 2-stage discovery and replication design, and then addressed whether the
identified variants also associated with older-onset disease.
Methods
Discovery population
The Genetics of Early Onset Stroke (GEOS) Study is a population-based case-control study
designed to identify genes associated with early-onset ischemic stroke and to characterize
interactions of identified stroke genes and/or SNPs with environmental risk factors. Partici-
pants (921 stroke cases and 941 controls) were recruited from the greater Baltimore-Washing-
ton area over 4-time periods between 1992–2008 [11]. The population is primarily composed
of two self-reported ethnic groups, European-Americans (Caucasians) (EA; 54.5%) and Afri-
can-Americans (AA; 40.4%), with the remaining 5.1% of individuals comprising other ethnici-
ties including Chinese, Japanese, other Asians, and other unspecified. Stroke cases were
hospitalized with a first cerebral infarction identified by discharge surveillance from one of the
59 hospitals in the greater Baltimore-Washington area and direct referral from regional neu-
rologists. Cases were enrolled in either the sub-acute or chronic post-stroke phases as based on
previously described case identification and enrollment procedures [8,11]. Ischemic strokes
with the following characteristics were excluded from participation: stroke occurring as an
immediate consequence of trauma; stroke within 48 hours after a hospital procedure, stroke
within 60 days after the onset of a non-traumatic subarachnoid hemorrhage, and cerebral
venous thrombosis. The abstracted hospital records of cases were reviewed and adjudicated
for ischemic stroke subtype by a pair of neurologists per previously published procedures
[12,13], with disagreements resolved by a third neurologist. The ischemic stroke subtype classi-
fication system retains information on all probable and possible causes, and is reducible to the
more widely used TOAST system [14] that assigns each case to a single category. All cases had
age of first stroke between 15–49 years and were recruited within three years of stroke.
Thrombomodulin-endothelial cell protein C receptor genetics and ischemic stroke risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0206554 November 1, 2018 3 / 12
Family Foundation in Australia. Elizabeth G Holliday
was supported by a Fellowship from the National
Heart Foundation and National Stroke Foundation
of Australia (ID: 100071). BRAINS: Bio-Repository
of DNA in Stroke (BRAINS) is partly funded by a
Senior Fellowship from the Department of Health
(UK) to P Sharma, the Henry Smith Charity and the
UK-India Education Research Institutive (UKIERI)
from the British Council. HPS: Heart Protection
Study (HPS) (ISRCTN48489393) was supported
by the UK Medical Research Council (MRC), British
Heart Foundation, Merck and Co (manufacturers of
simvastatin), and Roche Vitamins Ltd
(manufacturers of vitamins). Genotyping was
supported by a grant to Oxford University and CNG
from Merck and Co. Jemma C Hopewell
acknowledges support from the British Heart
Foundation (FS/14/55/30806). ISGS: Ischemic
Stroke Genetics Study (ISGS)/Siblings With
Ischemic Stroke Study (SWISS) was supported in
part by the Intramural Research Program of the
NIA, NIH project Z01 AG-000954-06. ISGS/SWISS
used samples and clinical data from the NIH-
NINDS Human Genetics Resource Center DNA and
Cell Line Repository (http://ccr.coriell.org/ninds),
human subjects protocol numbers 2003-081 and
2004-147. ISGS/SWISS used stroke-free
participants from the Baltimore Longitudinal Study
of Aging (BLSA) as controls. The inclusion of BLSA
samples was supported in part by the Intramural
Research Program of the NIA, NIH project Z01 AG-
000015-50, human subjects protocol number
2003-078. The ISGS study was funded by NIH-
NINDS grant R01 NS-42733 (JF Meschia). The
SWISS study was funded by NIH-NINDS grant R01
NS-39987 (J F Meschia). This study used the high-
performance computational capabilities of the
Biowulf Linux cluster at the NIH (http://biowulf.nih.
gov). MGH-GASROS: MGH Genes Affecting Stroke
Risk and Outcome Study (MGH-GASROS) was
supported by NINDS (U01 NS069208), the
American Heart Association/Bugher Foundation
Centers for Stroke Prevention Research 0775010N,
the NIH and NHLBI’s STAMPEED genomics
research program (R01 HL087676), and a grant
from the National Center for Research Resources.
The Broad Institute Center for Genotyping and
Analysis is supported by grant U54 RR020278
from the National Center for Research resources.
MILANO: Milano - Besta Stroke Register Collection
and genotyping of the Milan cases within CEDIR
were supported by the Italian Ministry of Health
(grant numbers: RC 2007/LR6, RC 2008/LR6; RC
2009/LR8; RC 2010/LR8; GR-2011-02347041).
FP6 LSHM-CT-2007-037273 for the PROCARDIS
control samples. WTCCC2: Wellcome Trust Case-
Control Consortium 2 (WTCCC2) was principally
For these genetic analyses, we included only Caucasians and African-Americans, and
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phenotype (e.g. cerebral autosomal dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL), mitochondrial encephalopathy with lactic acidosis and stroke-
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actively treated bacterial endocarditis at the time of the index stroke; neurosyphilis or other
CNS infections; neurosarcoidosis; severe sepsis with hypotension at the time of the index
stroke; cerebral vasculitis by angiogram and clinical criteria; post-radiation arteriopathy; left
atrial myxoma; major congenital heart disease; and cocaine use in the 48 hours prior to their
stroke.
Control participants without a history of stroke were identified by random-digit dialing.
Controls were balanced to cases by age and region of residence in each study period and were
additionally balanced for race/ethnicity in the latter two participant collection periods.
Traditional stroke risk factors and other study variables, including age, race/ethnicity, his-
tory of hypertension, diabetes, myocardial infarction (MI) and current smoking status (defined
as use within one month prior to event for cases and at a comparable reference time for con-
trols), were also collected during a standardized interview. Age, race/ethnicity, and cigarette
smoking status were determined by subject reports (or proxy report, if a participant was
unable to answer). Hypertension, diabetes mellitus, and MI were determined by asking study
participants (or a proxy) whether a physician had ever told them that they had the condition.
This study was conducted with the consent of all study subjects and was approved by the Uni-
versity of Maryland at Baltimore Institutional Review Board.
Genotyping
Genomic DNA was isolated from a variety of sample types, including cell line (55.2%), whole
blood (43.1%), mouthwash (0.4%) and buccal swab (0.05%). Whole genome amplification
(Qiagen REPLI-g kit, Valencia, CA, USA) was used to obtain sufficient DNA for genotyping in
1.3% of samples. The genotype data implemented in this study was obtained from two fixed-
content SNP panels developed by Illumina (Illumina, San Diego, CA, USA), a genome-wide
association (GWA) genotyping array, the HumanOmni1-Quad_v1-0_B BeadChip, and a car-
diovascular disease (CVD) SNP panel, the ITMAT-Broad-CARe array, that included THBD
and PROCR. Genotyping quality from both arrays was excellent with individual SNP call
rates > 98% and a between-panel concordance rate of 99.996% based on study duplicates (for
further details please see S1 File) [11].
SNP Selection and inclusion criteria
From each array, we extracted all SNPs in the THBD (chr 20: 22,974,270–22,978,301 bp) and
PROCR (chr 20: 33,223,435–33,228,826 bp) genes (NCBI Build 37) and then added all addi-
tional SNPs within 10kb upstream and downstream to capture regulatory regions. In total, we
identified 24 SNPs in THBD (17 GWA; 18 CVD; 11 overlap) and 22 SNPs in PROCR (22
GWA; 4 CVD; 4 overlap). Across both genes there were nine SNPs unique to European-Amer-
icans (EA; Caucasians) and six SNPs unique to African-Americans. There was an overlap of 15
SNPs between the two genotype sources with an average SNP call concordance rate between
platforms of>99%. Other predefined selection and quality control criteria included required;
1) HWE p-values >0.01, 2) Call rate> 98%, and MAF >0.01 in race-stratified samples.
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Analyses
Genetic association analyses were performed using the PLINK statistical software program
[15]. Prior to the association analysis we pruned the genotyped SNPs on the basis of linkage-
disequilibrium (LD), such that for any SNPs in high LD (r2�0.8) we retained only a single rep-
resentative SNP. This LD pruning was performed within each ethnic group separately using
PLINK. Within each ethnic group separately, we then used an additive logistic regression
model to test for association of genotype with stroke, adjusting for age and gender, and popu-
lation structure (principal components from GWAS array or CVD panel). Secondary analyses
were performed to determine if any observed associations were more prominent in those with
cardiovascular risk based on the presence of the traditional risk factors as described above and
previously [11]. For all association analyses, we defined a significant Boferroni-corrected p-
value as p<0.05 divided by the number of gene- and ethnicity-specific independent (LD-
pruned) SNPs (i.e., p = 0.05 / # independent LD-Pruned SNPs).
Replication and extension to older onset stroke
We sought to replicate any associated SNPs identified in the GEOS Study in an independent
set of early-onset stroke studies (the Genetics of Early Onset Stroke Consortium) previously
reported by Cheng et al. [16] after excluding the GEOS samples from the replication set, as
meta-analyzed implementing the GWAMA program. The studies included in the replication
were: CADISP, Cervical Artery Dissection and Ischemic Stroke Patients [17]; MILANO, Besta
Stroke Study; RACE, Risk Assessment of Cerebrovascular Events Study; SIFAP, Stroke in
Young Fabry Patients; and WTCCC2, Wellcome Trust Case–Control Consortium 2 [16]. The
details of each of replication cohort are available in the supplementary data of Cheng et al.
[16]. In short, only confirmed ischemic strokes, first ever or recurrent, were included in these
studies, TIAs and hemorrhagic strokes were excluded. SNPs whose associations replicated in
the Genetics of Early Onset Stroke Consortium were then tested for association with later- or
older-onset stroke via in silico lookup in the METASTROKE Consortium [17]; the mean age
of stroke onset ranged from 57.3–81.6 years among the 14 contributing cohorts of METAS-
TROKE (not including GEOS). Further details regarding the data collection, organization, and
relationships between METASTROKE and the other studies involved can be found in the S1
File and S1 Dataset.
The aggregated data that support the findings of this study are available from the corre-
sponding author and participating studies upon reasonable request as listed in the S1 Dataset.
Further, each study can be contacted to attain their data individually, and for the NIH funded
studies, study data is available via request from the database of Genotypes and Phenotypes
(dbGaP) @ https://www.ncbi.nlm.nih.gov/gap/.
Results
Characteristics of the young-onset stroke discovery and replication studies are provided in
Table 1. After exclusions, the GEOS Discovery Stage included 448 ischemic stroke cases
(mean age stoke-onset = 41.0 yrs) and 498 controls of EA ancestry, and 381 ischemic stroke
cases (mean age stroke-onset = 41.9 yrs) and 352 controls of AA ancestry. Further demo-
graphic and risk factor characteristics by case–control status for the GEOS Discovery Stage are
described in Table A in S1 File.
LD pruning resulted in 13 THBD SNPs in EAs and 13 THBD SNPs in AAs, and an addi-
tional 4 THBD SNPs in EAs on the CVD chip; and 5 PROCR SNPs in EAs and 11 PROCR
SNPs in AAs (see Table 2 and Table B in S1 File).
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Association analyses of the EA revealed a significant association of PROCR rs9574 with
ischemic stroke, with the rs9574C allele (MAF case/control = 0.49/0.41) associated with a
1.33-fold increased odds of stroke compared to the G allele (p = 0.003; Table 2). Another inde-
pendent PROCR SNP rs2069951 was also associated with ischemic stroke significantly in EA
(OR = 1.80, P = 0.006). None of the PROCR SNPs were associated with stroke in AA, nor were
any associations observed between THBD SNPs and stroke in either ethnic group. An explor-
atory analyses of stroke subtypes (e.g., TOAST-defined large artery (LA), small artery, cardi-
oembolic, and cryptogenic) did not reveal significant associations with any variants, although
the sample sizes were small (range: 33 LA to 230 cryptogenic) in EAs.
To further characterize the EA PROCR associations, we performed a secondary analysis to
evaluate the impact of concomitant vascular risk factors. We repeated the association analysis
with additional adjustment for vascular risk factors (i.e., hypertension, diabetes mellitus,
angina/MI, and current cigarette smoking) and found the association results to be essentially
unchanged (data not shown). However, when stratifying for the presence or absence of each
vascular risk factor, we observed a stronger, but non-statistically significant, association of
rs9574 and rs2069951 with stroke in the absence of each risk factor when considered sepa-
rately, with the direction of association similar across each risk factor (data not shown). To
obtain a more comprehensive picture, we therefore compared subjects with zero vascular risk
Fig 1. The thrombomodulin−protein C receptor (TM-EPCR) system located on the endothelial surface.
https://doi.org/10.1371/journal.pone.0206554.g001
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factors to those with at least one vascular risk factor. In the subset of EA participants without
vascular risk factors (n = 167 cases and 315 controls), both SNPs were more strongly associated
with stroke (rs9574, OR = 1.50, p = 0.0046; rs2069951, OR = 4.82, p = 0.0002; see Table 2).
Replication of the PROCR rs9574 association with early onset stroke
We sought to replicate the PROCR rs9574 and rs2069951 association in the Early-Onset Stroke
Consortium [16], with exclusion of the GEOS study. This replication sample included 3,676
cases and 21,118 controls. Only rs9574 replicated; the effect allele frequency of rs9574C was
0.39, with association analyses demonstrating an OR of 1.08 (p = 0.015) (Table 2). The ische-
mic stroke replication results of the LD-pruned PROCR SNPs among Caucasians in the
young-onset stroke consortium, inclusive and exclusive of GEOS, are shown in Table C in S1
File. There was no significant correlation between stroke subtypes and PROCR rs9574 in the
replication samples.
Older-onset stroke
To determine if PROCR rs9574 and/or the other previously identified LD-pruned SNPs were
associated with older-onset stroke, these SNPs were evaluated in the METASTROKE cohort
[18]. Lookups found no replication of these SNPs with ischemic stroke or in any subtype (data
not shown).
Discussion
We observed a significant association between PROCR rs9574 and early-onset ischemic stroke
that replicated in a large independent sample of early-onset ischemic stroke. Prior studies have
demonstrated that mutations in PROCR have been associated with venous thromboembolism
Table 1. Characteristics of participating studies.
Study Cases Controls Ancestry Country
Subjects,
n
Age, mean
(SD)
Male, n
(%)
Subjects,
n
Age, mean
(SD)
Male, n
(%)
External Control
Stage 1: Discovery Stage
GEOS EA 448 41.0 (7.0) 275 (61.4) 498 39.5 (6.7) 282 (56.6) No EA USA
GEOS AA 381 41.9 (6.8) 207 (54.3) 352 40.0 (6.8) 196 (55.7) No AA USA
Total 829 850
Stage 2: Replication Stage
CADISP 555 43.7 (9.9) 339 (61.1) 9259 N/A N/A No EA Belgium, France, Germany,
Italy, Switzerland, and Finland
MILANO 201 45.0 (10.4) 120 (60.9) 407 50.8 (8.1) 357 (87.8) No EA Italy
RACE 1 1218 50.1 (9.9) 638 (52.4) 1158 51.9 (7.9) 613 (53) PROMIS South
Asian
Pakistan
RACE 2 339 50.2 (9.2) 272 (80.4) 3295 60.9 (13.2) 1838
(55.8)
PROMIS South
Asian
Pakistan
SIFAP 981 41.7 (7.4) 599 (61.1) 1824 55.2 (11.6) 899 (49.3) KORA EA Germany
WTCCC2-UK 382 51.9 (7.3) 228 (59.7) 5175 52 2611
(50.5)
British Birth
Cohort and UK Blood
Service Control
EA UK
Total 3,676 21,118
AA indicates African ancestry; CADISP, Cervical Artery Dissection and Ischemic Stroke Patients; EA, European ancestry; GEOS, Genetics of Early-Onset Stroke;
MILANO, Besta Stroke Study; RACE, Risk Assessment of Cerebrovascular Events Study; SIFAP, Stroke in Young Fabry Patients; and WTCCC2, Wellcome Trust Case-
Control Consortium 2.
https://doi.org/10.1371/journal.pone.0206554.t001
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(VTE) [19] and myocardial infarction [20,21], as well as with late fetal loss during pregnancy
[22]. Specific to ischemic stroke, PROCR associations have been inconsistently reported [23,
24], which may in part be related to variations in the age and ethnicity of the populations evalu-
ated. Our study is the first to specifically identify and replicate PROCR associations in a young-
onset ischemic stroke population of European descent. Our failure to detect an association in
GEOS AA may reflect low power and/or that a true causal variant is not well tagged in African-
Americans. Our findings add to the growing evidence that prothrombotic mechanisms may be
more important for younger compared to older onset stroke as demonstrated with other estab-
lished prothrombotic variants including Prothrombin G20210A [8], Factor XI [10] and Factor
V Leiden [25]. This is also in line with the lack of association we observed between PROCR
rs9574 and older onset stroke in the METASTROKE lookup. Our findings are also consistent
with the hypothesis that PROCR (and perhaps by analogy other thrombosis-related genes) may
Table 2. PROCR association results of lead LD SNPs in Discovery GEOS European-Americans for all-stroke detailing allelic variants, effect allele frequencies
(EAF) and as stratified by the absence or presence of vascular risk factors, and lead LD SNP young-onset replication results.
Discovery: GEOS Replication: Young-Onset
Stroke Cohort without GEOS
(Meta-analysis of 6 studies)
448
cases
498
controls
Primary Model
(adjusted for age and
gender)
0 Risk Factors
(167 cases / 315 controls)
� 1 Risk Factors
(273 cases / 183
controls)
3671 Cases / 21119 Controls
rsID� LD_SNPs BP_
Build37
EAF EAF OR 95%CI P OR 95%CI P OR 95%CI P OR 95%CI P EAF
rs9574
(C/G)
(intronic)
rs945960
(intronic)
rs1415774
(intronic)
rs2069952
(intronic)
rs6088753
(intronic)
rs2378337
(intronic)
rs6087683
(intronic)
rs2065979
(intronic)
rs6088747
(intronic)
33764632 0.49 0.41 1.33 1.11–1.61 0.003 1.50 1.14–1.99 0.0046 1.23 0.94–1.61 0.1367 1.08 1.02–1.16 0.015 0.397
rs2069951
(G/A)
(intronic)
NA 33763764 0.96 0.93 1.80 1.18–2.75 0.006 4.82 2.14–10.89 0.0002 0.80 0.43–1.52 0.4870 1.08 0.93–1.27 0.331 0.956
rs6087682
(A/T)
(intronic)
rs6060278
(intronic)
33752897 0.80 0.75 1.26 1.01–1.58 0.050 1.33 0.96–1.87 0.0910 1.14 0.82–1.6 0.4510 1.03 0.97–1.12 0.368 0.766
rs867186
(A/G)
(missense)
rs7265317
(intronic)
rs11907011
(intronic)
rs8119351
(intronic)
33764554 0.91 0.90 1.18 0.86–1.64 0.311 1.63 1–2.69 0.0533 0.80 0.5–1.32 0.3789 1.10 0.98–1.26 0.133 0.865
rs1415775
(C/T)
(intronic)
NA 33765771 0.76 0.74 1.09 0.89–1.35 0.428 1.01 0.74–1.38 0.9694 1.23 0.92–1.67 0.1773 0.99 0.92–1.07 0.745 0.759
�EAF = Effect allele bolded
https://doi.org/10.1371/journal.pone.0206554.t002
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be more relevant, or easier to detect, in the setting of a paucity of standard vascular risk factors,
as these factors may induce risk via non-thrombotic mechanisms. This may again also partially
explain why we did not see replication in the older-onset METASTROKE population, which
also has a greater vascular risk factor burden. Differing genetic mechanisms may also partially
explain why African-Americans did not demonstrate the associations seen in their Caucasian
counterparts.
Strengths of our study include the well-phenotyped and relatively large young-onset discov-
ery sample size, as well as the large replication sample. Notably, GEOS cases are part of the
METASROKE as were other young-onset strokes, yet despite the inclusion of the GEOS sam-
ples, there was no association seen in this primarily older-onset cohort. A potential study limi-
tation relates to the replication sample, which is predominantly of European rather than
North-American origin, although the MAFs were roughly similar on both sides of the Atlantic.
Another limitation is that our discovery population-based design, with recruitment at over 50
regional hospitals, precluded consistent assessment of the presence of patent foramen ovale
(PFO) and potential paradoxical embolism among cases, given PROCR genetics are known to
increase the risk of venous thromboembolism. This is important because an established mech-
anism by which PROCR variation could cause ischemic stroke is via venous thrombosis and
paradoxical embolization. Our study was also limited to non-fatal ischemic strokes, so the pos-
sibility that our findings are due to a survival bias cannot be ruled out; though this is unlikely
given the low case-fatality rate in this population [26]. Another limitation is that our study pro-
vides no information about the role of PROCR in ischemic stroke among young adults with a
personal or family history of prior early-onset thrombotic events. Lastly, while some intronic
mutations can affect gene expression levels by introducing novel splice sites, activating novel
promoters (which may direct sense or antisense transcription causing alterations in mRNA,
miRNA or lncRNA expression), or by introducing/eliminating enhancer activity, our study
does not provide any such detailed mechanistic analyses. Despite these shortcomings, we have
identified several PROCR variants in strong LD that associate and replicate with ischemic
stroke among young Caucasians. While these findings are interesting, it is too early to assess
their clinical implications regarding anticoagulation and/or genetic testing, as examples. Fur-
ther replication and research are required to better understand these findings.
Conclusion
PROCR, but not THBD, polymorphisms are associated with early-onset ischemic stroke in
young Caucasians.
Supporting information
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